Bernard Kolodziej has become vice president of finance of Bruker AXS. Kolodziej was originally hired by Bruker AXS in 1997 and has been chief financial officer for the European operations of Bruker AXS since January 1999. Before joining the company, he held several operations and financial positions with the Siemens’ X-ray business. He has a master’s degree in business administration, finance, and production engineering from the University of Karlsruhe in Germany.
Mark Kay
has been appointed to its scientific advisory board of CombiMatrix. Kay is a professor of pediatrics and genetics at the Stanford University School of Medicine. He is also the director of Stanford’s program in human gene therapy.
Jeffrey Jeddeloh has been made director of biomarker discovery and detection at Orion Genomics. Jeddeloh’s primary responsibility will be to discover and develop assays for detecting epigenetic biomarkers linked to certain cancers. Jeddeloh joined Orion from the United States Army, where he served as a principal investigator at the US Army Medical Research Institute of Infectious Diseases. He received his PhD in molecular genetics from Washington University in St. Louis.
AVI BioPharma has appointed Peter O’Hanley as senior vice president of clinical development and regulatory affairs, and Ray Cummings as vice president of business development. O’Hanley comes to the company from Maxygen, where he was vice president of clinical development. He received his PhD and MD degrees from the Medical University of South Carolina, and obtained his MPH at the University of California, Berkeley. Cummings comes to AVI from Cummings Consulting, where he was founder and president. Before founding the firm, he was a vice president of business development at Aradigm. Cummings received his MBA from UC Berkeley. He also received an MS from Harvard University in biochemistry and molecular biology, and a BS in biological sciences from Stanford University.